Literature DB >> 11096546

Idiopathic Cardiomyopathy.

.   

Abstract

Idiopathic cardiomyopathy is a very common cause of heart failure today. It is a diagnosis of exclusion, and careful attention should be paid to the patient history to exclude all other causes. ACE inhibitors have become the first line therapy for all classes of left ventricular dysfunction. Doses of all therapeutic drugs for CHF should be up-titrated to maximum targeted dosages. New agents are being developed that offer increasing hope for therapies that will alter the natural history of heart failure.

Entities:  

Year:  2000        PMID: 11096546     DOI: 10.1007/s11936-000-0037-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  24 in total

Review 1.  Idiopathic dilated cardiomyopathy.

Authors:  G W Dec; V Fuster
Journal:  N Engl J Med       Date:  1994-12-08       Impact factor: 91.245

Review 2.  Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.

Authors:  G E Sander; J J McKinnie; S S Greenberg; T D Giles
Journal:  Prog Cardiovasc Dis       Date:  1999 Jan-Feb       Impact factor: 8.194

3.  Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.

Authors:  R Pacher; B Stanek; S Globits; R Berger; M Hülsmann; M Wutte; B Frey; M Schuller; E Hartter; E Ogris
Journal:  Eur Heart J       Date:  1996-08       Impact factor: 29.983

4.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

5.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

Review 6.  Compensatory and maladaptive responses to cardiac dysfunction.

Authors:  G S Francis; C Chu
Journal:  Curr Opin Cardiol       Date:  1995-05       Impact factor: 2.161

Review 7.  Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure.

Authors:  R K Garg; M Gheorghiade; S M Jafri
Journal:  Prog Cardiovasc Dis       Date:  1998 Nov-Dec       Impact factor: 8.194

Review 8.  Calcium channel blockers in cardiac failure.

Authors:  N Mahon; W J McKenna
Journal:  Prog Cardiovasc Dis       Date:  1998 Nov-Dec       Impact factor: 8.194

Review 9.  Parenteral inotropic support for advanced congestive heart failure.

Authors:  C V Leier; P F Binkley
Journal:  Prog Cardiovasc Dis       Date:  1998 Nov-Dec       Impact factor: 8.194

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  1 in total

1.  Sarcoidosis and the Heart.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.